Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24103740 | 0.86 | CYP2C19 (0.32) | EYA3CYP2C19KDRPREPCELA1 | |
| SCHEMBL25816065 | 0.85 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL24102976 | 0.81 | CYP2C19 (0.46) | EYA3CYP2C19 | |
| SCHEMBL20718288 | 0.79 | EYA3 (0.55) | EYA3CYP2C19 | |
| SCHEMBL25719653 | 0.79 | EYA3 (0.34) | EYA3KDRPREPCELA1 | |
| SCHEMBL22680471 | 0.78 | EYA3 (0.54) | EYA3CYP2C19 | |
| SCHEMBL24221837 | 0.76 | CYP2C19 (0.47) | EYA3CYP2C19 | |
| SCHEMBL24102960 | 0.75 | EYA3 (0.42) | EYA3CYP2C19 | |
| SCHEMBL20718531 | 0.73 | EYA3 (0.51) | EYA3CYP2C19 | |
| SCHEMBL24266787 | 0.73 | EYA3 (0.36) | EYA3CYP2C19KDRPREPCELA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020232156-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | EYA3 3141/4885CYP2C19 826/4885KDR 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.